RECENT ADVANCES IN UNDERSTANDING THE PATHOGENESIS OF THE HEMOLYTIC UREMIC SYNDROMES

被引:116
作者
KAPLAN, BS
CLEARY, TG
OBRIG, TG
机构
[1] Division of Nephrology, The Children's Hospital of Philadelphia, University of Philadelphia, Philadelphia
[2] Division of Pediatric Infectious Diseases, University of Texas Medical School at Houston, Houston, 77225, TX
[3] Department of Microbiology and Immunology, Albany Medical College, Albany, 12208, NY
关键词
Endothelial cells; Escherichia coli 0157:H7; Hemolytic uremic syndrome; Shiga-like toxin;
D O I
10.1007/BF00857676
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
One of the requirements for an agent to cause hemolytic uremic syndrome (HUS) is its ability to injure endothelial cells. Shiga-like toxin (SLT) can do this. SLT is produced by Escherichia coli and Shigella dysenteriae serotype 1; both have been implicated as causes of typical HUS. Endothelial cells have receptors (GB3) for SLT and the toxin can inhibit eukaryotic protein synthesis, thereby causing cell death. Glomerular endothelial cell injury or death results in a decreased glomerular filtration rate and many of the perturbations seen in HUS. It is no longer certain that hemolysis is the result of a microangiopathy. Cell injury results in release of von Willebrand multimers; if these are ultra-large, thrombosis may ensue. There is also increasing evidence that neutrophils have a role in the pathogenesis of typical HUS. Streptococcus pneumoniae can also cause HUS and care must be taken to avoid giving plasma to patients with S. pneumoniae-associated HUS. There is compelling evidence that types of HUS are inherited by autosomal recessive and autosomal dominant modes. Patients with autosomal recessive HUS may have recurrent episodes. Mortality and morbidity rates are high for the inherited forms. © 1990 IPNA.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 93 条
  • [31] Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K., Site of action of verotoxin (VT2) from E. coli 0157∶H7 and of Shigatoxin on eukargotic ribosomes, Eur J Biochem, 171, pp. 45-50, (1988)
  • [32] Saxena S.K., O'Brien A.D., Ackerman E.J., Shiga toxin, Shigalike toxin II variant, and ricin are all single site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes, J Biol Chem, 264, pp. 596-601, (1989)
  • [33] Obrig T.G., Moran T.P., Brown J.E., The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis, Biochem J, 244, pp. 287-294, (1987)
  • [34] Fontaine A., Arondel J., Sansonetti P.J., Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a tox mutant of Shigella dysenteriae 1, Infect Immun, 56, pp. 3099-3109, (1988)
  • [35] Obrig T.G., Del Vecchio P.J., Karmali M.A., Petric M., Moran T.P., Judge T.K., Pathogenesis of haemolytic-uraemic syndrome, Lancet, 2, (1987)
  • [36] Wiley R.G., Donohue-Rolfe A., Keusch G.T., Oeltmann T.N., Selective destruction of vagal sensory neurons using Shigella cytotoxin, Methods Enzymol, 165, pp. 250-253, (1988)
  • [37] de Chadarevian J-P, Kaplan B.S., The hemolytic uremic syndrome of childhood, Perspect Pediatr Pathol, 4, pp. 465-502, (1978)
  • [38] Boyd B., Lingwood C., Verotoxin receptor glycolipid in human renal tissue, Nephron, 51, pp. 207-210, (1989)
  • [39] Bergstein J.M., Bang N.U., Plasminogen activator inhibitor-1 (PAI-1) is the circulating inhibitor of fibrinolysis (PAI-HUS) in the hemolytic-uremic syndrome, Am Soc Nephrol Abst, 36, (1989)
  • [40] Remuzzi G., Misiani R., Marchesi D., Livio M., De Gaetano G., Donati M.B., Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?, Lancet, 2, pp. 871-872, (1978)